Female sex is a risk factor for insomnia across the lifespan, with prevalence approximately 1.4 times higher in women than men. This gap widens significantly after the age of 45, the typical age of perimenopause onset, and continues into the postmenopausal decade. Understanding why helps to navigate the treatment options that are most likely to be effective for this specific presentation.
How Female Insomnia Differs
Women over 45 with insomnia are more likely than younger adults to present with sleep maintenance difficulty (waking in the night) rather than sleep onset difficulty (difficulty falling asleep). They are more likely to report anxiety and low mood as comorbidities, and more likely to have vasomotor symptoms that contribute to sleep fragmentation. The combination of hormonal, neurochemical, and psychological factors means that addressing any single component in isolation will often produce only partial improvement.
The Hot Flush-Insomnia Cycle
Vasomotor symptoms cause sleep fragmentation, which produces anxiety, which lowers the arousal threshold, which makes subsequent hot flushes more likely to produce full waking rather than brief arousal. This self-reinforcing cycle can maintain insomnia long after vasomotor symptoms themselves have reduced in frequency. Breaking the cycle requires addressing both the vasomotor component and the conditioned hyperarousal that has developed.
Progesterone's Specific Role
The decline in progesterone in perimenopause removes an important endogenous sleep-promoting effect, as progesterone and allopregnanolone are GABA-A receptor modulators. This is relevant to HRT prescribing: micronised progesterone (Utrogestan) may provide better sleep benefits than synthetic progestogens (like medroxyprogesterone acetate) because micronised progesterone more closely replicates natural progesterone's effect on GABA receptors. Some women notice sleep improvement specifically from the progesterone component of their HRT regimen.
Optimal Treatment Strategy
- First-line: CBT-I as the standard insomnia treatment, addressing conditioned arousal regardless of underlying cause
- For vasomotor-driven disruption: HRT, particularly body-identical oestradiol and micronised progesterone, is the most effective intervention
- Acupuncture: evidence for both vasomotor symptom reduction and direct sleep improvement
- Melatonin: useful for circadian stabilisation; 0.5 to 3mg taken 90 minutes before target sleep time
- Exercise: particularly important; reduces both vasomotor symptoms and the anxiety that perpetuates insomnia
- Addressing depression: depression is both a cause and consequence of insomnia in this age group; the two must be treated concurrently
Sources
- Mong JA, Cusmano DM. (2016). Sex differences in sleep: impact of biological sex and sex steroids. Philosophical Transactions of the Royal Society B, 371(1688), 20150110.
- Polo-Kantola P, et al. (1998). When does estrogen replacement therapy improve sleep quality? American Journal of Obstetrics and Gynecology, 178(5), 1002-1009.
- Drake CL, et al. (2014). Insomnia and diabetes: a bidirectional relationship. Diabetes Care, 37(9), 2523-2531.